Medical/Pharmaceuticals

InxMed Announces Clinical Collaboration with MSD to Evaluate IN10018 in Combination with Pembrolizumab

SHANGHAI, Jan. 7, 2020 /PRNewswire/ -- InxMed (Shanghai) Co., Ltd., a clinical stage biotech company dedicated to developing innovative, individualized medicines with international impact, today announced that the company has entered into a clinical collaboration with a subsidiary of Merck & C...

2020-01-07 08:25 748

Japanese Clinical Study of DiscGenics' Cell Therapy for Disc Degeneration Passes Initial Safety Review

SALT LAKE CITY and TOKYO, Jan. 7, 2020 /PRNewswire/ -- DiscGenics, Inc., a clinical stage biopharmaceutical company focused on developing regenerative cell-based therapies that alleviate pain and restore function in patients with degenerative diseases of the spine, today announced that IDCT has p...

2020-01-07 08:00 428

Inovio Provides Update on Clinical Program Plans for 2020

Inovio to present 2020 program plans at Biotech Showcase 2020 Conference PLYMOUTH MEETING, Pennsylvania, Jan. 6, 2020 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced that Inovio's President & CEO, Dr. J. Joseph Kim will present a corporate update of the company's clinical progr...

2020-01-06 21:00 1000

Antengene Corporation Appoints Former Celgene China GM John Chin as Chief Business Officer

SHANGHAI and PHILADELPHIA, Jan. 6, 2020 /PRNewswire/ -- Antengene Corporation today announced its appointment of Mr.John Chin, MBA, as Chief Business Officer (CBO). He will be responsible for the company's global business development and commercialization, and will report directly to Dr.Jay Mei, ...

2020-01-06 20:00 686

12th Consecutive Year Leading United States in Organ Donation for Gift of Life Donor Program

PHILADELPHIA, Jan. 6, 2020 /PRNewswire/ -- For the 12th consecutive year, Gift of Life Donor Program is the nation's leading organ procurement organization (OPO), coordinating the most life-saving organs for transplant among all 58 U.S. OPOs.

2020-01-06 20:00 302

BAVENCIO Significantly Improved Overall Survival in Patients With Locally Advanced or Metastatic Urothelial Carcinoma

Not intended for US-, Canada- and UK-based media  - At the planned interim analysis, Phase III JAVELIN Bladder 100 study met the primary endpoint of prolonging overall survival (OS) as a first-line maintenance treatment versus standard of care - BAVENCIO is the first immunotherapy to signifi...

2020-01-06 20:00 3793

Dr. Nalini Rajamannan Comments on FDA Congressional Letter to Senate Finance Committee After Kaiser Health News Reveals Access to Exempt FDA Database

SHEBOYGAN, Wis., Jan. 6, 2020 /PRNewswire/ -- Dr. Nalini Rajamannan -- a specialist for patients with valvular heart disease in Most Sacred Heart of Jesus Cardiology,Sheboygan, WI -- confirms today that patients finally may get answers about whether medical devices placed in their bodies are test...

2020-01-06 19:00 282

Abcam Announces Successful Acquisition of Expedeon's Proteomics and Immunology Business, Enhancing Its Conjugation Capability

- Includes leading protein conjugation technologies and industry brands Lightning-Link® and CaptSure™ - Opportunity to combine Expedeon and Abcam's technologies to create new products to support research and diagnostic development CAMBRIDGE, England, Jan. 6, 2020 /PRNewswire/ -- Abcam plc, a glo...

2020-01-06 15:00 381

Yisheng Biopharma and Tavotek Biotherapeutics Announce Strategic Research Alliance for Development of YS-ON-001/002 and Tavo-301/303 Combination Therapy for Cancer Treatment

GAITHERSBURG, Md. and AMBLER, Pa., Jan. 6, 2020 /PRNewswire/ -- Yisheng Biopharma Co., Ltd. ("Yisheng Biopharma"), a biopharmaceutical company focusing on research, development, manufacturing, sales and marketing of immunological biologics and vaccines, and Tavotek Biotherapeutics, a biotech c...

2020-01-06 09:00 394

Fountain Medical Appoints Mr. Ling Zhen as the Co-Chairman and Chief Executive Officer

BEIJING and SHANGHAI, Jan. 2, 2020 /PRNewswire/ -- Fountain Medical Development Limited ("Fountain Medical" or "Company"), a clinical stage CRO dedicated to offering high-quality one-stop services to pharmaceutical and medical device clients, announced today that Mr.Ling Zhen, J.D., M.B.A., is ap...

2020-01-02 09:30 1101

WuXi Biologics Congratulates OncoImmune on FDA Clearance of IND Application for Next Generation anti-CTLA-4 Antibody ONC-392

SHANGHAI, Jan. 2, 2020 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, congratulates its partner OncoImmune on the U.S. Food and Drug ...

2020-01-02 08:08 442

CF PharmTech Closes US$ 90 Million Financing Round to Accelerate Global Development of Respiratory Drugs

SHUZHOU, China, Jan. 2, 2020 /PRNewswire/ -- CF PharmTech, Inc., a pharmaceutical company with a vision to provide quality and affordable respiratory drug products globally, announced it has raised a $90 million Series E investment led by New Alliance Capital. The investment included participati...

2020-01-02 08:00 1562

Oncologie Selected as Top 100 Innovative Pharmaceutical Company in China

SHANGHAI, Dec. 27, 2019 /PRNewswire/ -- Oncologie, a biopharmaceutical company with innovative oncology therapeutics supported by a biomarker platform to select patients, today announced that it has been selected as a Top 100 innovative pharmaceutical company inChina by VCBeat, a renowned healthc...

2019-12-27 21:00 992

New Major Order From China

STOCKHOLM, Dec. 27, 2019 /PRNewswire/ -- Bactiguard has received a new order from Well Lead Medical (Well Lead) inChina. The order will be delivered promptly and generate revenues in the fourth quarter of approximatelySEK 16.5 million. "This is the second order from Well Lead outside the initial...

2019-12-27 19:37 1026

Focusing on Cutting-edge Biopharmaceutical Technologies, Boosting the Industry to Achieve Innovation and Development

SHANGHAI, Dec. 25, 2019 /PRNewswire/ -- To seize the ever-changing opportunities in the new era and to meet the ever-growing market demands, the annual gala of the biopharmaceutical industry---bioLIVE China 2020, will be held again at Hall W4 in the SNIEC onJune 22-24, 2020. The exhibition, co-l...

2019-12-25 12:55 886

EpiVax Announces Record Year for Growth in 2019 and Sets New Milestones for 2020

PROVIDENCE, Rhode Island, Dec. 24, 2019 /PRNewswire/ -- EpiVax ("EpiVax, Inc.") continues its record-breaking performance and growth in personnel in 2019 while identifying new milestones to aspire to in 2020. The Business Development team closed 15% more contracts over 2018 and acquired two ne...

2019-12-24 16:35 815

TOWA PHARMACEUTICAL CO., LTD. reaches an agreement with ESTEVE to acquire ESTEVE's generic division, Pensa Investments

The operation will accelerate TOWA's overseas business presence and provide high-quality and value-added generic medicines to patients. OSAKA, Japan and BARCELONA, Spain, Dec. 23, 2019 /PRNewswire/ -- TOWA PHARMACEUTICAL CO.,LTD. (Osaka, Japan) (TOWA) and ESTEVE (Barcelona, Spain) announced toda...

2019-12-23 17:17 576

WuXi Biologics Receives "Special Award to Investors in Ireland" from Asia Matters

DUBLIN, Dec. 23, 2019 /PRNewswire/ -- December 23, 2019 – WuXi Biologics ("WuXi Bio") (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, announced that it has received the "Special Awa...

2019-12-23 16:26 471

Holmusk and NHCS Extend Collaboration to Improve Heart Disease Care

SINGAPORE, Dec. 23, 2019 /PRNewswire/ -- Holmusk and National Heart Centre Singapore announced that they have extended their collaboration agreement to improve care for patients with coronary artery disease using machine learning and data analytics, untilDecember 2020. This will build upon the wo...

2019-12-23 13:43 554

iView Announces First Patient Treated in Phase 2 Clinical Trial Program Evaluating IVIEW-1201 in Patients with Acute Adenoviral Conjunctivitis

HYDERABAD, India, Dec. 23, 2019 /PRNewswire/ -- iView Therapeutics Inc. today announced that the first patient has been dosed in the Phase 2 IVIEW-1201-01-AIC clinical trial program assessing the efficacy of IVIEW-1201 in patients (age ≥15 years) with Acute Adenoviral Conjunctivitis. First subjec...

2019-12-23 08:42 508
123456 ... 143